DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Information source: University of Alabama at Birmingham
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mesothelioma

Intervention: Zometa (zoledronic acid) (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: University of Alabama at Birmingham

Official(s) and/or principal investigator(s):
Francisco Robert, M.D., Principal Investigator, Affiliation: University of Alabama at Birmingham

Summary

The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG PET scans.

Clinical Details

Official title: A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Evaluation of the tumor response rate following zoledronic acid

Secondary outcome: Evaluation of the duration of tumor response

Detailed description: This pilot study will examine the effect of bisphosphonate (zoledronic acid) in patients with malignant mesothelioma. Evaluation will be limited to patients with standard (CT scans) and functional instruments (FDG PET Scans) of tumor assessment after the administration of standard doses of zoledronic acid (4 mg IV every 3 weeks). We will also explore the biologic effect of zoledronic acid in patients using new serum markers as well as several blood level markers.

Eligibility

Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Males and females > 18 years of age

- Life expectancy of at least 2 months

- Histologically confirmed unresectable malignant pleural mesothelioma (MPM)

- Measurable disease by CT Scan criteria and/or positive metabolic activity of 18F-FDG

PET Scan criteria at screening

- ECOG Performance Status of 0-2

- Laboratory and clinical results within 2 weeks prior to Day 1 must be as follows:

1. ANC ≥ 1. 5 x 109/L 2. Platelet Count ≥ 100 x 109/L 3. Hemoglobin ≥ 9g/dL 4. Serum bilirubin ≤ 1. 5 x upper limit of normal (ULN) 5. AST ≤ 2. 5 x ULN 6. ALT ≤ 2. 5 x ULN 7. ALK-P ≤ 3 x ULN 8. Serum creatinine ≤ 1. 8mg/dL

9. Calculated Serum Creatinine Clearance 40 - > 60ml/min

- Female subjects of childbearing potential and all male subjects must be surgically

sterile or consent to use a medically acceptable method of contraception throughout the trial.

- Willing and able to provide written informed consent.

Exclusion Criteria:

- Known central nervous system (CNS) tumor involvement

- Evidence of other active malignancy requiring treatment

- Clinically significant heart disease (e. g., congestive heart failure of New York

Heart Association Class 3 or 4 angina not well controlled by medication, or myocardial infarction within 6 months)

- Known infection with HIV or hepatitis

- Clinically significant arrhythmias demonstrated on electrocardiogram (ECG). Note:

subjects with chronic atrial arrhythmia, i. e., atrial fibrillation or paroxysmal supraventricular tachycardia (SVT) are eligible.

- Active, serious systemic disease, including active bacterial or fungal infection.

- Subjects undergoing invasive dental procedures, significant periodontal disease or

history of osteonecrosis of the jaw.

- Treatment within 4 weeks of the start of the trial with other systemic anticancer

therapy.

- Breastfeeding, pregnant, or likely to become pregnant during the clinical trial.

Locations and Contacts

University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
Additional Information

Starting date: June 2009
Last updated: May 6, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017